Publication | Open Access

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Immunosuppressive M2-like MacrophagesMedicineMetronomic TherapyImmunologyEmactuzumab Single AgentImmune Checkpoint InhibitorImmunotherapyOncologyRadiation Oncology